Overview
What it is.
Tesamorelin is a GHRH analog with one of the deepest research records in this category, most established for its effect on visceral (abdominal) fat in formal clinical study populations. It remains a frequent reference compound in broader GH-axis and body-composition research.
Research Areas
- Studied for its role in visceral (abdominal) fat reduction
- Studied for its potential role in body-composition research more broadly
- Studied for its potential role in supporting natural growth hormone production
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
Tesamorelin is a GHRH analog that is FDA-approved under the brand name Egrifta (and its reformulations Egrifta SV and Egrifta WR) specifically for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is the most rigorously studied peptide on this page, with a full Phase 3 program behind its approved use.
Tesamorelin binds the GHRH receptor on the pituitary and stimulates the body's own pulsatile GH release, which in turn raises IGF-1 and drives changes in fat metabolism — particularly a reduction in visceral (deep abdominal) fat, the specific effect its approval is built on.
Use Cases Explored
- Studied and FDA-approved for reducing visceral (deep abdominal) fat in HIV-associated lipodystrophy
- Studied for its potential role in body composition more broadly, including off-label use
- Studied for its potential role in supporting natural growth hormone and IGF-1 levels
The Evidence
Two Phase 3, randomized, double-blind, placebo-controlled trials (816 patients)
The FDA approval rested on two multicenter Phase 3 studies (26-week main phase, 26-week extension) in HIV-infected patients with lipodystrophy. Pooled results across 806 participants showed roughly a 15.4% reduction in visceral adipose tissue versus placebo at 26 weeks (p<0.001), the strongest human evidence base of any peptide covered here.
Effect reverses after stopping treatment
In the trial's crossover design, patients who switched from tesamorelin to placebo generally saw visceral fat return within a few months — the approved effect requires continued treatment and is not a permanent change.
FDA approval is narrow, not a general growth-hormone-support endorsement
The FDA explicitly noted long-term cardiovascular safety was not established at approval, stated tesamorelin should not be used for general weight loss, and required it be avoided in patients with active malignancy given its GH-stimulating mechanism. Off-label use outside the approved lipodystrophy indication has not been through the same trial process.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Questions
Tesamorelin FAQ
Questions
Tesamorelin FAQ
Why does tesamorelin have a deeper clinical research record than most GH-axis peptides?+
It has been studied through formal clinical trial programs at a scale most peptides in this category have not, which is why researchers frequently use it as a reference compound.
Growth Hormone
Tesamorelin
A GHRH analog most established in the research literature for visceral fat reduction.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
